Chitosan Nanoparticles: Comprehensive Analysis Of Synthesis, Functionalization, And Biomedical Applications

Molecular Composition And Structural Characteristics Of Chitosan Nanoparticles

Chitosan nanoparticles are constructed from chitosan, a linear polysaccharide composed of β-(1→4)-linked D-glucosamine and N-acetyl-D-glucosamine units 278. The degree of deacetylation (DD) critically influences nanoparticle formation and biological activity: formulations optimized for immunotherapy typically employ chitosan with DD ≈90% and molecular weight (MW) ranging from 5 kDa to 80 kDa 78, whereas mucosal vaccine delivery systems utilize chitosan with MW 10–500 kDa and DD >40% 2. Lower molecular weight chitosan oligosaccharides (MW 20–100 kDa) demonstrate enhanced water solubility and physiological activity, making them suitable for intelligent drug delivery systems 17.

The cationic nature of chitosan arises from protonated amino groups (–NH₃⁺) at physiological pH, conferring mucoadhesive properties and electrostatic interaction with negatively charged cell membranes, nucleic acids, and anionic biopolymers 511. This positive surface charge (zeta potential typically +30 to +35 mV) promotes cellular internalization via adsorptive endocytosis and enhances stability in biological fluids 13. Cross-linking strategies—such as ionic gelation with sodium tripolyphosphate (TPP), covalent bonding with glutaraldehyde, or complexation with anionic polymers like fucoidan or polysialic acid—further stabilize nanoparticle architecture and modulate release kinetics 5101213.

Quaternization And Dual Derivatization For Enhanced Functionality

Quaternized chitosan derivatives, such as N,N,N-trimethyl chitosan (TMC), exhibit permanent positive charge independent of pH, improving solubility and transfection efficiency 613. Dual derivatization with cationic amino acids (e.g., arginine) and hydrophilic polyols (e.g., gluconic acid) significantly enhances gene transfer efficiency in vivo by balancing electrostatic DNA binding with endosomal escape capability 616. For instance, chitosan functionalized with arginine and gluconic acid demonstrated superior transfection compared to unmodified chitosan in preclinical gene delivery models 16.

Fucoidan-quaternized chitosan nanoparticles combine the immunostimulatory properties of fucoidan (a sulfated polysaccharide) with the cationic delivery capacity of TMC, yielding nanoparticles with enhanced adjuvant activity for vaccine formulations 5. Similarly, polysialic acid-based TMC gel nanoparticles (diameter ≈100 ± 25 nm, zeta potential >+30 mV) achieve controlled release of methotrexate for rheumatoid arthritis therapy, with improved stability and reduced systemic toxicity compared to conventional chitosan carriers 13.

Synthesis Methodologies And Process Optimization For Chitosan Nanoparticles

Ionic Gelation Technique

Ionic gelation remains the most widely adopted method for chitosan nanoparticle synthesis due to its simplicity, mild conditions, and absence of organic solvents 2781014. The process involves dropwise addition of an anionic cross-linker (typically TPP at 0.5–1.0% w/v) to a chitosan solution (0.1–0.2% w/v in acetate buffer, pH 4.0–5.5) under constant stirring (500–3000 rpm) 1015. Electrostatic interactions between protonated amino groups of chitosan and negatively charged phosphate groups of TPP induce spontaneous nanoparticle formation, yielding particles with diameters of 100–400 nm depending on chitosan MW, DD, chitosan:TPP mass ratio, and pH 210.

For antigen-loaded vaccine formulations, chitosan (DD ≈90%, MW 5–80 kDa) is mixed with antigen prior to TPP addition, achieving encapsulation efficiencies >85% and particle sizes of 200–350 nm suitable for dendritic cell uptake 78. The pH of the chitosan solution (optimal range 5.5–6.5) critically affects particle size distribution and zeta potential: lower pH (<5.0) increases protonation and particle aggregation, while higher pH (>6.5) reduces cross-linking efficiency 210.

Microemulsion Cross-Linking For Ultra-Small Nanoparticles

Water-in-oil microemulsion systems enable synthesis of ultra-small chitosan nanoparticles (≤100 nm) with narrow size distribution 18. In this approach, chitosan dissolved in aqueous acetic acid is dispersed as nanodroplets within a continuous oil phase (e.g., cyclohexane) stabilized by surfactants (e.g., Triton X-100, hexanol). Addition of a cross-linker (e.g., glutaraldehyde) to the microemulsion induces intra-droplet polymerization, with final particle size determined by water-to-surfactant ratio (ω₀) rather than chitosan concentration 18. This method permits covalent attachment of imaging agents (fluorescent dyes, quantum dots) or targeting ligands during synthesis, yielding multifunctional nanoparticles for diagnostic imaging and theranostic applications 18.

Solvent-Free Cross-Linking And Novel Derivatization

A novel solvent-free cross-linking method employs direct reaction between chitosan and bifunctional reagents (e.g., dicarboxylic acids, diisocyanates) in solid state or aqueous suspension, forming amide or urethane linkages without organic solvents 12. This approach yields cross-linked chitosan derivatives that spontaneously form nanoparticles upon dispersion in aqueous media, with enhanced stability across pH 3–9 and resistance to microbial degradation 12. The resulting nanoparticles exhibit broad-spectrum biological activities (antimicrobial, antioxidant, immunomodulatory) and serve as versatile platforms for bioactive agent delivery 12.

Encapsulation Of Bioactive Compounds

Encapsulation of hydrophobic drugs (e.g., curcumin, berberine, gemcitabine) or essential oils (e.g., garlic oil) is achieved by dissolving the compound in ethanol or emulsifying in the chitosan solution prior to cross-linking 491517. For garlic essential oil-loaded chitosan nanoparticles (particle size 200–400 nm), the oil is emulsified in chitosan solution using high-speed homogenization, followed by TPP-induced gelation, yielding spherical nanoparticles with antifungal activity against Aspergillus and Fusarium species 4. Magnetic targeting is incorporated by co-encapsulating superparamagnetic iron oxide nanoparticles (SPIONs) with the drug, enabling external magnetic field-guided accumulation at tumor sites 9.

Physicochemical Characterization And Quality Control Parameters

Particle Size, Zeta Potential, And Morphology

Dynamic light scattering (DLS) and transmission electron microscopy (TEM) are standard techniques for determining hydrodynamic diameter and morphology of chitosan nanoparticles 241013. Optimized formulations typically yield spherical particles with mean diameters of 100–400 nm and polydispersity index (PDI) <0.3, indicating narrow size distribution 41013. Zeta potential measurements (by electrophoretic light scattering) confirm surface charge: values >+30 mV indicate colloidal stability and predict efficient cellular uptake, while values between +20 and +30 mV suggest moderate stability requiring lyophilization or refrigeration for long-term storage 513.

For fucoidan-quaternized chitosan nanoparticles, zeta potential ranges from +25 to +35 mV depending on fucoidan:TMC ratio, with higher TMC content yielding more positive charge 5. Polysialic acid-TMC nanoparticles exhibit zeta potential >+30 mV at polysialic acid:TMC ratio of 0.5:1, ensuring stability during systemic circulation 13.

Encapsulation Efficiency And Drug Loading

Encapsulation efficiency (EE%) and loading capacity (LC%) are determined by indirect methods: nanoparticles are separated by centrifugation (15,000–20,000 rpm, 30 min, 4°C), and free drug in the supernatant is quantified by UV-Vis spectroscopy or HPLC 91517. For chitosan nanoparticles loaded with pasak bumi root extract (20–40 mg/mL), EE% exceeds 96% with particle sizes of 127–147 nm and zeta potential of −33 to −35 mV (negative due to anionic compounds in the extract) 15. Trimethyl chitosan nanoparticles encapsulating gemcitabine achieve LC% of 15–25% with sustained release over 72 hours in pH 7.4 phosphate buffer 9.

Stability In Biological Fluids And Storage

Chitosan nanoparticles demonstrate pH-dependent stability: particles prepared at pH 5.5–6.5 remain stable in simulated gastric fluid (pH 1.2) for 2 hours and in simulated intestinal fluid (pH 6.8) for 6 hours without significant aggregation 10. Incorporation of glucomannan (a neutral polysaccharide) enhances stability in acidic and basic media, enabling long-term storage (>12 months at 4°C) without particle aggregation or drug leakage 10. Freeze-drying (lyophilization) with cryoprotectants (e.g., trehalose, mannitol at 5–10% w/v) preserves nanoparticle integrity and facilitates reconstitution with minimal size increase (<10%) 78.

Mechanisms Of Cellular Uptake And Intracellular Trafficking

Chitosan nanoparticles enter cells primarily via clathrin-mediated endocytosis and macropinocytosis, driven by electrostatic attraction between cationic nanoparticles and anionic cell membrane components (sialic acid residues, phospholipids) 211. Following internalization, nanoparticles reside in early endosomes (pH ≈6.0), where protonation of chitosan amino groups induces osmotic swelling ("proton sponge effect"), leading to endosomal membrane disruption and cytoplasmic release of cargo 611.

For gene delivery applications, dual-derivatized chitosan nanoparticles (arginine-gluconic acid modification) exhibit enhanced endosomal escape due to arginine-mediated membrane destabilization and buffering capacity of gluconic acid 616. This results in 3–5-fold higher transfection efficiency compared to unmodified chitosan in HEK293 and CHO cell lines 16.

Ultrasound-assisted delivery further enhances intracellular uptake through non-bubble-based sonoporation: application of focused ultrasound (1 MHz, 0.5–1.0 W/cm², 30–60 seconds) induces transient membrane permeabilization, increasing nanoparticle internalization by 2–4-fold without compromising cell viability (>85% viability post-treatment) 19. This technique is particularly effective for drug-loaded chitosan nanoparticles targeting solid tumors, where ultrasound is applied externally to the tumor site 19.

Applications In Drug Delivery And Controlled Release Systems

Cancer Chemotherapy And Targeted Delivery

Chitosan nanoparticles serve as carriers for chemotherapeutic agents, reducing systemic toxicity and enhancing tumor accumulation via the enhanced permeability and retention (EPR) effect 915. Trimethyl chitosan nanoparticles loaded with gemcitabine and SPIONs (particle size 150–200 nm) demonstrate magnetic targeting capability: application of an external magnetic field (0.3–0.5 T) increases nanoparticle accumulation in lung tumor xenografts by 3-fold compared to non-magnetic controls, resulting in 60% tumor volume reduction over 21 days 9.

Chitosan nanoparticles encapsulating pasak bumi root extract (containing eurycomanone and other quassinoids) exhibit selective cytotoxicity against cancer cell lines (IC₅₀ = 15–30 μg/mL in MCF-7 and HeLa cells) with minimal toxicity to normal fibroblasts (IC₅₀ >100 μg/mL), attributed to passive targeting via EPR and pH-responsive release in acidic tumor microenvironment (pH 6.5–6.8) 15.

Brain-Targeted Drug Delivery

Surfactant-coated chitosan nanoparticles (double-coating technique) enable brain targeting by enhancing blood-brain barrier (BBB) penetration 1. The inner chitosan core encapsulates the drug, while the outer surfactant layer (e.g., polysorbate 80, Pluronic F-68) facilitates adsorption of apolipoprotein E from blood plasma, triggering receptor-mediated transcytosis across brain endothelial cells 1. This formulation is under investigation for delivery of neuroprotective agents and chemotherapeutics for glioblastoma treatment 1.

Mucosal Vaccine Delivery And Immunotherapy

Chitosan nanoparticles function as adjuvants and delivery vehicles for mucosal vaccines, enhancing antigen uptake by M cells in Peyer's patches and stimulating both humoral (IgA, IgG) and cellular (CD4⁺, CD8⁺ T cells) immune responses 278. Antigen-loaded chitosan nanoparticles (chitosan MW 5–80 kDa, DD ≈90%, particle size 200–350 nm) induce 5–10-fold higher antigen-specific IgG titers compared to soluble antigen in murine immunization models 78.

For SARS-CoV-2 vaccine development, chitosan nanoparticles (MW 10–500 kDa, pH 5.5–6.5) encapsulating spike protein or receptor-binding domain (RBD) elicit robust mucosal IgA responses following intranasal administration, providing protection against viral challenge in preclinical studies 2. The mucoadhesive properties of chitosan prolong antigen residence time at mucosal surfaces, enhancing antigen presentation to dendritic cells 2.

Fucoidan-quaternized chitosan nanoparticles demonstrate superior adjuvant activity compared to conventional chitosan or aluminum hydroxide, attributed to synergistic immunostimulation by fucoidan (TLR4 agonist) and chitosan (NLRP3 inflammasome activator) 5. These nanoparticles are cost-effective alternatives to CpG oligonucleotides for veterinary and human vaccines 5.

Applications In Agriculture: Biopesticides And Plant Growth Promotion

RNA Interference-Based Pest Control

Chitosan nanoparticles serve as carriers for double-stranded RNA (dsRNA) targeting essential genes in insect pests, enabling topical or systemic delivery of RNA interference (RNAi) agents 11. For cotton pest management, chitosan nanoparticles (particle size 150–250 nm) loaded with dsRNA targeting Agrotis ipsilon chitinase II gene (AgraChSII) are applied as foliar sprays 11. The chitosan matrix protects dsRNA from degradation by nucleases in the insect gut and facilitates uptake through the cuticle or midgut epithelium 11.

Field trials demonstrate that dsRNA-loaded chitosan nanopartic